Asset profile
Ifinatamab Deruxtecan
Antibody–drug conjugate
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ifinatamab Deruxtecan: this drug | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| 7MW3711 | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| BNT324 | Phase 3 | Antibody–drug conjugate | B7-H3 | ||
| GSK5764227 | Phase 3 | Small molecule | B7-H3 | ||
| YL201 | Phase 3 | Small molecule | B7-H3 | ||
| 177Lu-BetaBart | Phase 1/2 | Radiopharmaceutical | B7-H3 | ||
| ITC-6146RO | Phase 1 | Antibody–drug conjugate | B7-H3 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
April 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (5)
January 2028 (2)
June 2028 (2)
July 2028 (1)
What to watch
2029 (1)
April 2029 (1)
What to watch
2030 (1)
November 2030 (1)
What to watch
2031 (2)
2032 (4)
January 2032 (1)
What to watch
February 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.